drugset / Trial / NCT04216953
MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma
NaSingle-groupOpen-labelTreatment
Summary
The proposed study conducted in adult and pediatric patients aims to evaluate the safety and clinical activity of atezolizumab + cobimetinib in advanced/metastatic soft tissue sarcomas (up to 80 patients).
Timeline
- Start
- 2020-02-12
- Primary completion
- 2024-12-01
- Completion
- 2025-03-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 15 mg/kg | — |
| Subject | Atezolizumab | Monoclonal antibody | 840 mg | — |
| Subject | Cobimetinib | Small molecule | 1 mg/kg | Oral |
| Subject | Cobimetinib | Small molecule | 60 mg | Oral |